This antibody is a mouse IgG1 isotype. The AB0046 antibody specifically bound to an epitope containing residues within a portion of mouse MMP9 corresponding to the portion containing amino acids 159-166 of human MMP9.
Figure 1 Serum concentrations of anti-MMP-9 and isotype control antibodies in mice.
Mean serum concentrations (± SD) from individual mice receiving standard TB treatment in combination with anti-MMP-9 (AB0046, red circle) or isotype control (AB5123, black circle) are depicted. Mice were sacrificed at week 2 (n = 13) and 6 (n = 13) during the dosing phase, and at week 8 (n = 13), 10 (n = 7), and 12 (n = 7) during the antibody elimination phase.
Ordonez, A. A., Pokkali, S., Kim, S., Carr, B., Klunk, M. H., Tong, L.,... & Gossage, D. L. (2018). Adjunct antibody administration with standard treatment reduces relapse rates in a murine tuberculosis model of necrotic granulomas. PloS one, 13(5), e0197474.
Figure 2 shows the results of endoscopic evaluation, performed on all groups of animals on study days 10 and 14 (day of termination).
Panel A shows mean endoscopy score (+/−SEM) at days 6-14, with arrows indicating days of AB0046 (or other treatment) administration. Panel B shows mean endoscopy score (+/−SEM) at day 14 for each group, with asterisks indicating significant reduction in disease (which was observed for AB0046 and ENBREL® treatment groups at Day 14). Endoscopic score reflects the most severe lesion observed for each animal.
Figure 3 shows body weight and diarrhea results for the study.
The area under the curve (AUC) was calculated for body weight changes and diarrhea incidence by the trapezoidal rule method. Treatment with anti-MMP9 antibody (AB0046) was protective against body weight loss due to DSS-induced colitis and comparable to the effect of ENBREL® treatment. The incidence of diarrhea was similarly reduced with AB0046 and ENBREL® treatment.
Figure 4 shows a reduction of endoscopic disease by anti-MMP9 antibody (AB0047) treatment in the DSS colitis model.
Figure 5 shows the results of endoscopic evaluation, performed on all groups of animals on indicated days in the prophylactic treatment study.
Panel A shows mean endoscopy score (+/−SEM) at days 6-14, with arrows indicating days of AB0046 (or other treatment) administration. Panel B shows mean endoscopy score (+/−SEM) at day 10 for each group, with asterisks indicating significant reduction in disease (which was observed for AB0046 and ENBREL® treatment groups at Day 14). Endoscopic score reflects the most severe lesion observed for each animal.
Figure 6 shows decrease in primary tumor growth in an established colorectal tumorigenesis model (HCT116).
The left panel shows decreased change in tumor volume; the right panel shows decreased final tumor weight at day 32 after initiation of treatment (with p-values derived from Mann-Whitney test and bars representing group mean±SEM).
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
CAT | Product Name | Application | Type |
---|---|---|---|
DrMAB-1048 | Recombinant Mouse Anti-Human MMP9 Antibody Fab Fragment | LMNX, ELISA, WB, IF | Fab |
HPAB-0199-FY-F(E) | Human Anti-MMP9 Recombinant Antibody (clone DX-2802); Fab Fragment | ELISA, FC | Human Fab, λ |
HPAB-0200-FY-F(E) | Human Anti-MMP9 Recombinant Antibody (clone M0279-A03); Fab Fragment | ELISA, FC | Human Fab |
HPAB-M0359-YC-F(E) | Human Anti-MMP9 Recombinant Antibody (clone AB0045); Fab Fragment | ELISA | Humanized Fab |
HPAB-1320-FY-S(P) | Human Anti-MMP9 Recombinant Antibody; scFv Fragment (HPAB-1320-FY-S(P)) | Activ | Human scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-533CL | Anti-Human MMP9 Recombinant Antibody (GS-5745) | WB, Inhib | Antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-0824CL | Human Anti-MMP9 Recombinant Antibody (TAB-0824CL) | ELISA | Human IgG4 |
TAB-0825CL | Human Anti-MMP9 Recombinant Antibody (TAB-0825CL) | ELISA | Human IgG4 |
TAB-0824CL-S(P) | Human Anti-MMP9 Recombinant Antibody; scFv Fragment (TAB-0824CL-S(P)) | ELISA | Human scFv |
TAB-0825CL-S(P) | Human Anti-MMP9 Recombinant Antibody; scFv Fragment (TAB-0825CL-S(P)) | ELISA | Human scFv |
TAB-0824CL-F(E) | Human Anti-MMP9 Recombinant Antibody; Fab Fragment (TAB-0824CL-F(E)) | ELISA | Human Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-0826CL | Mouse Anti-MMP9 Recombinant Antibody (TAB-0826CL) | Inhib, ELISA, IHC | Mouse IgG |
TAB-0827CL | Mouse Anti-MMP9 Recombinant Antibody (TAB-0827CL) | ELISA | Mouse IgG |
TAB-0826CL-S(P) | Mouse Anti-MMP9 Recombinant Antibody; scFv Fragment (TAB-0826CL-S(P)) | ELISA | Mouse scFv |
TAB-0826CL-F(E) | Mouse Anti-MMP9 Recombinant Antibody; Fab Fragment (TAB-0826CL-F(E)) | ELISA | Mouse Fab |
TAB-0827CL-F(E) | Mouse Anti-MMP9 Recombinant Antibody; Fab Fragment (TAB-0827CL-F(E)) | ELISA | Mouse Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
PSBC-174 | Mouse Anti-MMP9 Recombinant Antibody (clone SDS3); scFv Fragment | ELISA, Neut | Mouse scFv |
HPAB-0027-YC-S(P) | Mouse Anti-MMP9 Recombinant Antibody; scFv Fragment (HPAB-0027-YC-S(P)) | FC | Mouse scFv |
HPAB-0028-YC-S(P) | Human Anti-MMP9 Recombinant Antibody (clone G03-VH-GL-V1/ G06-VL-GL1); scFv Fragment | Neut | Human scFv |
HPAB-M0359-YC-S(P) | Human Anti-MMP9 Recombinant Antibody (clone AB0045); scFv Fragment | ELISA | Humanized scFv |
HPAB-1320-FY-F(E) | Human Anti-MMP9 Recombinant Antibody; Fab Fragment (HPAB-1320-FY-F(E)) | Activ | Human Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
BRD-0717MZ | Chicken Anti-MMP9 Polyclonal IgY | WB | Chicken antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
NEUT-1748CQ | Recombinant Mouse Anti-MMP9 Antibody (VMC204) | Inhib, IHC-Fr, IP, IHC-P, WB, IHC, ICC | IgG1 |
CAT | Product Name | Application | Type |
---|---|---|---|
MOR-2263 | Hi-Affi™ Recombinant Rabbit Anti-MMP9 Monoclonal Antibody (DS2263AB) | FC, IHC-P, WB | IgG |
MOR-4331 | Hi-Affi™ Recombinant Rabbit Anti-MMP-9 Monoclonal Antibody (SI420DS) | ELISA | IgG |
MOR-4332 | Hi-Affi™ Recombinant Rabbit Anti-MMP-9 Monoclonal Antibody (SI421DS) | ELISA | IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-002ML | Anti-Human MMP9 Recombinant Antibody (Andecaliximab) | ELISA, IHC, FC, IP, IF, FuncS | IgG4, κ |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0199-FY | Human Anti-MMP9 Recombinant Antibody (clone DX-2802) | ELISA, FC | Human IgG1, λ |
HPAB-0200-FY | Human Anti-MMP9 Recombinant Antibody (clone M0279-A03) | ELISA, FC | Human IgG |
HPAB-0513LY | Mouse Anti-MMP9 Recombinant Antibody (clone M4) | FC | Mouse IgG |
HPAB-0514LY | Mouse Anti-MMP9 Recombinant Antibody (clone M12) | FC | Mouse IgG |
MRO-1014-CN | Recombinant Rabbit Anti-MMP9 Monoclonal Antibody (JA80-73) | WB, IF, IHC, FC | Rabbit IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
AFC-TAB-002ML | Afuco™ Anti-MMP9 ADCC Recombinant Antibody (Andecaliximab), ADCC Enhanced | ELISA, IHC, FC, IP, IF, FuncS | ADCC enhanced antibody |
There are currently no Customer reviews or questions for HPAB-M0311-YC. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.